Fakty i mity na temat miejscowych inhibitorów kalcyneuryny
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
kwi 11, 2013
Słowa kluczowe:
inhibitory kalcyneuryny, działania niepożądane, bezpieczeństwo
##plugins.themes.bootstrap3.article.main##
Abstrakt
Inhibitory kalcyneuryny należą do leków o udokumentowanym działaniu przeciwzapalnym i przeciwalergicznym. Zarówno pimekrolimus, jak i takrolimus w postaci preparatów do stosowania miejscowego są zarejestrowane do leczenia chorych na atopowe zapalenie skóry, jednak z powodzeniem stosowane są również w innych dermatozach zapalnych. Odznaczają się dużą skutecznością i zazwyczaj są dobrze tolerowane przez pacjentów.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Czarnecka-Operacz , M., & Sadowska-Przytocka , A. (2013). Fakty i mity na temat miejscowych inhibitorów kalcyneuryny. Alergoprofil, 9(1), 5-10. Pobrano z https://journalsmededu.pl/index.php/alergoprofil/article/view/751
Numer
Dział
Artykuł
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Drake L.A., Dinehart S.M., Farmer E.R et al.: Guidelines for care for the use of topical glucocorticoids. J. Am. Acad. Dermatol. 1996, 35: 615-619.
2. Kino T., Hatanaka H., Hashimoto M. et al.: FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. 1987, 40: 1256-1265.
3. Silny W., Czarnecka-Operacz M.: Skuteczność i bezpieczeństwo miejscowych inhibitorów kalcyneuryny w leczeniu atopowego zapalenia skóry. Przegl. Dermatol. 2009, 96: 99-103.
4. Bochelen D., Rudin M., Sauter A.: Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J. Pharmacol. Exp. Ther. 1999, 288: 653-659.
5. Kempers S., Boguniewicz M., Carter E. et al.: A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0,03% in the treatment of pediatric patients with moderate atopic dermatitis. J. Am. Acad. Dermatol. 2004, 51: 515-525.
6. Spergel J.M.: Immunology and treatment of atopic dermatitis. Am. J. Clin. Dermatol. 2008, 9: 233-244.
7. Nowicki R. et al.: Pimekrolimus w atopowym zapaleniu skóry. Terapia 2012, 12: 17-19.
8. Buchau A.S., Schauber J., Hultsch T., Stuetz A., Gallo R.L.: Pimecrolimus enhances TLR2/6 – induced expression of antimicrobial peptides in keratinocytes. J. Invest. Dermatol. 2008, 128: 2646-2654.
9. Luger T., Nieto A.: Pimecrolimus cream 1% in infants with mild-to moderate atopic dermatitis: efficacy and safety results from a 5-year randomized study. EADV 2012, PRA12-0252.
10. Schurmeyer-Horst F., Luger T.A., Bohm M.: Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology 2007, 214(1): 99-100.
11. Schliemann S., Kelterer D., Bauer A. et al.: Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis 2008, 58: 299-306.
12. Canpolat F., Cemil B.C., Tatlican S. et al.: Pimecrolimus 1% cream is effective in the treatment of psoriasis in an infant. Eur. J. Dermatol. 2009, 19: 168-169.
13. Freeman A.K., Linowski G.J., Brady C. et al.: Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J. Am. Acad. Dermatol. 2003, 48: 564-568.
14. Ang-Tiu C.U., Meghrajani C.F., Maano C.C.: Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert Rev. Clin. Pharmacol. 2012, 5: 91-97.
15. Braza T.J., DiCarlo J.B., Soon S.L. et al.: Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br. J. Dermatol. 2003, 148: 1242-1244.
16. Samycia M., Lin A.N.: Efficacy of topical calcineurin inhibitors in lichen planus. J. Cutan. Med. Surg. 2012, 16: 221-229.
17. Kim C.Y., Kim J.G., Oh C.W.: Treatment of oral lichen sclerosus with 1% pimecrolimus cream. Ann. Dermatol. 2010, 22: 326-329.
18. Sotiriou E., Apalla Z., Patsatsi A. et al.: Topical tacrolimus for recalcitrant vulvar lichen sclerosus. Eur. J. Dermatol. 2009, 19: 515-516.
19. Wong R., Lin A.N.: Efficacy of topical calcineurin inhibitors in vitiligo. Int. J. Dermatol. 2013, 52(4): 491-6.
20. Vilela F.A., Carneiro S., Ramos-e-Silva M.: Treatment of morphea or localized scleroderma: review of the literature. J. Drugs Dermatol. 2010, 9: 1213-1219.
21. Khondker L., Wahab M.A., Khan S.I.; Efficacy of topical application of Pimecrolimus cream in the treatment of discoid lupus erythematosus. Mymensingh. Med. J. 2012, 21: 259-264.
22. Kim M.B., Kim G.W., Park H.J. et al.: Pimecrolimus 1% cream for the treatment of rosacea. J. Dermatol. 2011, 38: 1135-1139.
23. Czarnecka-Operacz M., Jenerowicz D.: Topical calcineurin inhibitors in the treatment of atopic dermatitis: an update on safety issues. J. Dtsch. Dermatol. Ges. 2012, 10: 167-172.
24. Stӓnder S., Luger T.A.: Antipruritische Wirkung von Pimecrolimus und Tacrolimus. Autarzt. 2003, 54: 413-417.
25. Ho V.C., Gupta A., Kaufmann R. et al.: Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J. Pediatr. 2003, 142: 155-162.
26. Luger T., Van Leent E.J., Graeber M. et al.: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br. J. Dermatol. 2001, 144: 788-794.
27. Queille-Roussel C., Paul C., Duteil L. et al.: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br. J. Dermatol. 2001, 144: 507-513.
28. Kempers S., Boguniewicz M., Carter E. et al.: A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J. Am. Acad. Dermatol. 2004, 51: 515-525.
29. Paller A.S., Lebwohl M., Fleischer A.B. Jr. et al.: Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J. Am. Acad. Dermatol. 2005, 52: 810-822.
30. Fleischer A.B. Jr., Abramovits W., Breneman D. et al.: Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J. Dermatolog. Treat. 2007, 18: 151-157.
31. Kirsner R.S., Heffernan M.P., Antaya R.: Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. Acta Derm. Venereol. 2010, 90: 58-64.
32. Naylor M., Elmets C., Jaracz E. et al.: Non melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J. Dermatol. Treat. 2005, 16: 149-153.
33. Arellano F.M., Wentworth C.E., Arana A. et al.: Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J. Invest. Dermatol. 2007, 127: 808-816.
34. Papp K.A., Breuer K., Meurer M. et al.: Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J. Am. Acad. Dermatol. 2005, 52: 247-253.
35. Yin Z.Q., Zhang W.M., Song G.X. et al.: Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis. J. Dermatol. 2012; 39: 520-526.
36. Perotti V., Baldassari P., Bersani I. et al.: NFATc2 is a potential therapeutic target in human melanoma. J. Invest. Dermatol. 2012, 132: 2652-2660.
2. Kino T., Hatanaka H., Hashimoto M. et al.: FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. 1987, 40: 1256-1265.
3. Silny W., Czarnecka-Operacz M.: Skuteczność i bezpieczeństwo miejscowych inhibitorów kalcyneuryny w leczeniu atopowego zapalenia skóry. Przegl. Dermatol. 2009, 96: 99-103.
4. Bochelen D., Rudin M., Sauter A.: Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J. Pharmacol. Exp. Ther. 1999, 288: 653-659.
5. Kempers S., Boguniewicz M., Carter E. et al.: A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0,03% in the treatment of pediatric patients with moderate atopic dermatitis. J. Am. Acad. Dermatol. 2004, 51: 515-525.
6. Spergel J.M.: Immunology and treatment of atopic dermatitis. Am. J. Clin. Dermatol. 2008, 9: 233-244.
7. Nowicki R. et al.: Pimekrolimus w atopowym zapaleniu skóry. Terapia 2012, 12: 17-19.
8. Buchau A.S., Schauber J., Hultsch T., Stuetz A., Gallo R.L.: Pimecrolimus enhances TLR2/6 – induced expression of antimicrobial peptides in keratinocytes. J. Invest. Dermatol. 2008, 128: 2646-2654.
9. Luger T., Nieto A.: Pimecrolimus cream 1% in infants with mild-to moderate atopic dermatitis: efficacy and safety results from a 5-year randomized study. EADV 2012, PRA12-0252.
10. Schurmeyer-Horst F., Luger T.A., Bohm M.: Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology 2007, 214(1): 99-100.
11. Schliemann S., Kelterer D., Bauer A. et al.: Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis 2008, 58: 299-306.
12. Canpolat F., Cemil B.C., Tatlican S. et al.: Pimecrolimus 1% cream is effective in the treatment of psoriasis in an infant. Eur. J. Dermatol. 2009, 19: 168-169.
13. Freeman A.K., Linowski G.J., Brady C. et al.: Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J. Am. Acad. Dermatol. 2003, 48: 564-568.
14. Ang-Tiu C.U., Meghrajani C.F., Maano C.C.: Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert Rev. Clin. Pharmacol. 2012, 5: 91-97.
15. Braza T.J., DiCarlo J.B., Soon S.L. et al.: Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br. J. Dermatol. 2003, 148: 1242-1244.
16. Samycia M., Lin A.N.: Efficacy of topical calcineurin inhibitors in lichen planus. J. Cutan. Med. Surg. 2012, 16: 221-229.
17. Kim C.Y., Kim J.G., Oh C.W.: Treatment of oral lichen sclerosus with 1% pimecrolimus cream. Ann. Dermatol. 2010, 22: 326-329.
18. Sotiriou E., Apalla Z., Patsatsi A. et al.: Topical tacrolimus for recalcitrant vulvar lichen sclerosus. Eur. J. Dermatol. 2009, 19: 515-516.
19. Wong R., Lin A.N.: Efficacy of topical calcineurin inhibitors in vitiligo. Int. J. Dermatol. 2013, 52(4): 491-6.
20. Vilela F.A., Carneiro S., Ramos-e-Silva M.: Treatment of morphea or localized scleroderma: review of the literature. J. Drugs Dermatol. 2010, 9: 1213-1219.
21. Khondker L., Wahab M.A., Khan S.I.; Efficacy of topical application of Pimecrolimus cream in the treatment of discoid lupus erythematosus. Mymensingh. Med. J. 2012, 21: 259-264.
22. Kim M.B., Kim G.W., Park H.J. et al.: Pimecrolimus 1% cream for the treatment of rosacea. J. Dermatol. 2011, 38: 1135-1139.
23. Czarnecka-Operacz M., Jenerowicz D.: Topical calcineurin inhibitors in the treatment of atopic dermatitis: an update on safety issues. J. Dtsch. Dermatol. Ges. 2012, 10: 167-172.
24. Stӓnder S., Luger T.A.: Antipruritische Wirkung von Pimecrolimus und Tacrolimus. Autarzt. 2003, 54: 413-417.
25. Ho V.C., Gupta A., Kaufmann R. et al.: Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J. Pediatr. 2003, 142: 155-162.
26. Luger T., Van Leent E.J., Graeber M. et al.: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br. J. Dermatol. 2001, 144: 788-794.
27. Queille-Roussel C., Paul C., Duteil L. et al.: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br. J. Dermatol. 2001, 144: 507-513.
28. Kempers S., Boguniewicz M., Carter E. et al.: A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J. Am. Acad. Dermatol. 2004, 51: 515-525.
29. Paller A.S., Lebwohl M., Fleischer A.B. Jr. et al.: Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J. Am. Acad. Dermatol. 2005, 52: 810-822.
30. Fleischer A.B. Jr., Abramovits W., Breneman D. et al.: Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J. Dermatolog. Treat. 2007, 18: 151-157.
31. Kirsner R.S., Heffernan M.P., Antaya R.: Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. Acta Derm. Venereol. 2010, 90: 58-64.
32. Naylor M., Elmets C., Jaracz E. et al.: Non melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J. Dermatol. Treat. 2005, 16: 149-153.
33. Arellano F.M., Wentworth C.E., Arana A. et al.: Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J. Invest. Dermatol. 2007, 127: 808-816.
34. Papp K.A., Breuer K., Meurer M. et al.: Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J. Am. Acad. Dermatol. 2005, 52: 247-253.
35. Yin Z.Q., Zhang W.M., Song G.X. et al.: Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis. J. Dermatol. 2012; 39: 520-526.
36. Perotti V., Baldassari P., Bersani I. et al.: NFATc2 is a potential therapeutic target in human melanoma. J. Invest. Dermatol. 2012, 132: 2652-2660.